Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

Renal impairment is associated with a poor prognosis in patients with multiple myeloma (MM), and more treatment options are needed. The pharmacokinetics of elotuzumab, a humanized IgG1 monoclonal antibody, combined with lenalidomide and dexamethasone, is not significantly different between patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Berdeja, Jesus, Jagannath, Sundar, Zonder, Jeffrey, Badros, Ashraf, Kaufman, Jonathan L., Manges, Robert, Gupta, Manish, Tendolkar, Amol, Lynch, Mark, Bleickardt, Eric, Paliwal, Prashni, Vij, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857171/
https://www.ncbi.nlm.nih.gov/pubmed/26795075
http://dx.doi.org/10.1016/j.clml.2015.12.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857171/
https://www.ncbi.nlm.nih.gov/pubmed/26795075
http://dx.doi.org/10.1016/j.clml.2015.12.007

Ejemplares similares